{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:08:49Z","timestamp":1789348129951,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Almirall (US)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Truncal acne is common, and the psychosocial burden may be underestimated as patients most often complain of facial acne. The Acne Symptom and Impact Scale (ASIS) is a 17-item patient-reported outcome (PRO) measure designed to assess the signs and impacts of acne vulgaris. ASIS has previously been validated in a prospective, non-interventional study as a reliable PRO instrument for facial acne. In a pilot study, ASIS, and an additional 10 new questions that focused on the concerns of patients (ASIS-C), were given to 10 patients with moderate-to-severe truncal acne vulgaris who received 3 months of monotherapy with oral sarecycline, a narrow-spectrum tetracycline-class antibiotic. ASIS-C questionnaires were also given to 10 acne-free control subjects. Average ASIS-C answers decreased by 4% for Signs, 15% for Impact, and 16% for Concerns in the 10 patients, with greater decreases of 5% for Signs, 20% for Impact, and 19% for Concerns in the 60% of patients whose truncal acne was clear or almost clear after 12 weeks of sarecycline treatment. In this study, sarecycline was effective in reducing the psychosocial burden associated with truncal acne based on the ASIS-C PRO measures.<\/jats:p>","DOI":"10.3390\/antibiotics12010094","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:31:27Z","timestamp":1672900287000},"page":"94","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Sarecycline on the Acne Symptom and Impact Scale and Concerns in Moderate-to-Severe Truncal Acne in Open-Label Pilot Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Angela Yen","family":"Moore","sequence":"first","affiliation":[{"name":"Arlington Center for Dermatology, Arlington, TX 76011, USA"},{"name":"Arlington Research Center, Arlington, TX 76011, USA"},{"name":"Department of Dermatology, Baylor University Medical Center, Dallas, TX 75246, USA"},{"name":"Department of Medical Education, School of Medicine, Texas Christian University, Fort Worth, TX 76017, USA"},{"name":"Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Hurley","sequence":"additional","affiliation":[{"name":"Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7372-913X","authenticated-orcid":false,"given":"Stephen Andrew","family":"Moore","sequence":"additional","affiliation":[{"name":"Arlington Center for Dermatology, Arlington, TX 76011, USA"},{"name":"Arlington Research Center, Arlington, TX 76011, USA"},{"name":"Department of Dermatology, Baylor University Medical Center, Dallas, TX 75246, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Moore","sequence":"additional","affiliation":[{"name":"Arlington Center for Dermatology, Arlington, TX 76011, USA"},{"name":"Arlington Research Center, Arlington, TX 76011, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7892-8798","authenticated-orcid":false,"given":"Ilana","family":"Zago","sequence":"additional","affiliation":[{"name":"Department of Medical Education, School of Medicine, Texas Christian University, Fort Worth, TX 76017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"ref_1","first-page":"205","article-title":"Truncal Acne: A Neglected Entity","volume":"18","author":"Lynde","year":"2019","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bunick, C., Keri, J., Tanaka, S., Furey, N., Damiani, G., Johnson, J., and Grada, A. (2021). Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040439"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jdin.2021.03.002","article-title":"Impact of facial and truncal acne on quality of life: A multi-country population-based survey","volume":"3","author":"Tan","year":"2021","journal-title":"JAAD Int."},{"key":"ref_4","first-page":"597","article-title":"A closer look at truncal acne vulgaris: Prevalence, severity, and clinical significance","volume":"6","author":"Bikowski","year":"2007","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_5","first-page":"333","article-title":"Development of a new patient-reported outcome measure for facial acne: The Acne Symptom and Impact Scale (ASIS)","volume":"13","author":"Alexis","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_6","first-page":"552","article-title":"Validation of a New Patient-Reported Outcome Measure for Facial Acne: The Acne Symptom and Impact Scale (ASIS)","volume":"14","author":"Hudgens","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e01297-18","DOI":"10.1128\/AAC.01297-18","article-title":"Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris","volume":"63","author":"Zhanel","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","first-page":"987","article-title":"Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: Results from two identically designed, phase 3, randomized, double-blind clinical trials","volume":"17","author":"Moore","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_9","first-page":"45","article-title":"Management of Truncal Acne Vulgaris with Topical Dapsone 7.5% Gel","volume":"11","author":"Kircik","year":"2018","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1468-3083.2004.00946.x","article-title":"Disease-specific quality of life is associated with anxiety and depression in patients with acne","volume":"18","author":"Yazici","year":"2004","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D34HP8N68P","article-title":"Acne in adolescents: Quality of life, selfesteem, mood, and psychological disorders","volume":"17","author":"Dunn","year":"2011","journal-title":"Dermatol. Online J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1111\/bjd.16099","article-title":"Risk of depression among patients with acne in the UK: A population-based cohort study","volume":"178","author":"Vallerand","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/jid.2010.264","article-title":"Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: A population-based study","volume":"131","author":"Halvorsen","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamadermatol.2022.2742","article-title":"Projective Personification Approach to the Experience of People with Acne and Acne Scarring-Expressing the Unspoken","volume":"158","author":"Tan","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1001\/jamadermatol.2022.3911","article-title":"Use of Patient-Reported Outcomes in Acne Vulgaris and Rosacea Clinical Trials from 2011 to 2021: A Systematic Review","volume":"158","author":"Ly","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-4632.2009.03806.x","article-title":"Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents","volume":"48","author":"Kaymak","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/jamadermatol.2022.2260","article-title":"Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients with Acne Vulgaris: A Systematic Review of Measure Development and Measurement Properties","volume":"158","author":"Hopkins","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1001\/jamadermatol.2022.2293","article-title":"Analysis of Content and Phrasing of Health-Related Quality-of-Life Patient-Reported Outcome Measures Used in Patients with Acne","volume":"158","author":"Yoon","year":"2022","journal-title":"JAMA. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jdv.18009","article-title":"TRASS: A global approach to assess the severity of truncal acne","volume":"36","author":"Auffret","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","first-page":"534","article-title":"The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris","volume":"16","author":"Hoffman","year":"2017","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_21","first-page":"e5217567","article-title":"Topical Treatment of Truncal Acne with Tretinoin Lotion 0.05% and Azelaic Acid Foam","volume":"2020","author":"Miller","year":"2020","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_22","first-page":"26","article-title":"A Review of the Safety and Efficacy of Benzoyl Peroxide (5.3%) Emollient Foam in the Management of Truncal Acne Vulgaris","volume":"3","author":"Bikowski","year":"2010","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_23","first-page":"830","article-title":"The effect of benzoyl peroxide 9.8% emollient foam on reduction of Propionibacterium acnes on the back using a short contact therapy approach","volume":"11","author":"Leyden","year":"2012","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40261-013-0065-1","article-title":"Tazarotene foam versus tazarotene gel: A randomized relative bioavailability study in acne vulgaris","volume":"33","author":"Jarratt","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","article-title":"Randomized phase 3 evaluation of trifarotene 50 \u03bcg\/g cream treatment of moderate facial and truncal acne","volume":"80","author":"Tan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/jdv.15794","article-title":"Long-term safety and efficacy of trifarotene 50 \u03bcg\/g cream, a first-in-class RAR-\u03b3 selective topical retinoid, in patients with moderate facial and truncal acne","volume":"34","author":"Fowler","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/000155501750208119","article-title":"A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk","volume":"81","author":"Cunliffe","year":"2001","journal-title":"Acta Derm. Venereol."},{"key":"ref_28","first-page":"148","article-title":"Truncal acne vulgaris: The relative roles of topical and systemic antibiotic therapy","volume":"6","year":"2007","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_29","first-page":"160","article-title":"Efficacy, Safety, and Tolerability of Topical Dapsone Gel, 7.5% for Treatment of Acne Vulgaris by Fitzpatrick Skin Phototype","volume":"17","author":"Taylor","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_30","first-page":"634","article-title":"Management of Truncal Acne with Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials","volume":"20","author":"Baldwin","year":"2021","journal-title":"J. Drugs Dermatol. JDD"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/1\/94\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:00:13Z","timestamp":1760119213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/1\/94"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["antibiotics12010094"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12010094","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}